Lecanemab for Early Onset Familial Alzheimer's Disease

NCT06883019 · Recruiting

Last updated 2026-05-28

This clinical trial is testing the drug lecanemab in people who have early-onset familial Alzheimer's disease to see how it affects their cognitive function.

Status Recruiting Currently enrolling participants.

Type Observational

Participants 114 people Planned (estimated).

Who can join Ages 18–65 · all sexes

Timeline Started 2025-03 · est. completion 2027-08

Where 15 sites · China

What this study is testing ClinicalTrials.gov NCT06883019 ↗

Description as written by the study sponsor.

The goal of this observational study is to learn about the efficacy of Lecanemab treatment for early-onset familial Alzheimer's disease (AD) in patients under 65 years of age with a family history of AD. Participants will receive Lecanemab at a dosage of 10 mg/kg every two weeks for a total of 18 months and will undergo cognitive assessments, PET and MRI scans, blood/fluid tests and whole genome sequencing. The study will explore the effects of genetic and hereditary factors on the efficacy of Lecanemab treatment in early-onset familial AD patients.

Main thing measured	Chang of CDR-SB score
Sponsor	RenJi Hospital
Conditions studied	Alzheimer Disease
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06883019 ↗